Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer

Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer

Source: 
MedCity News
snippet: 

FDA approval of Amgen drug sotorasib (Lumakras) makes the small molecule the first compound authorized by the regulator for treating cancers characterized by a KRAS G12C mutation. Mutated KRAS proteins had long been regarded "undruggable" targets.